augmented by central pain mechanisms, including central sensitisation. Measures of the level of central involvement in pain could inform clinical decision making. Self-report characteristics of depression, anxiety, cognitive difficulties, catastrophising, sleep disturbance, fatigue, and widespread pain distribution together contribute to a Central Mechanisms Trait which is associated with central sensitisation and OA knee pain

**Objectives:** Using self-report questionnaire data from the Osteoarthritis Initiative Cohort Study (OAI) we aimed to evaluate the prognostic performance of baseline CMT for pain at 24-months.

**Methods:** OAI participants with knee OA or at risk of knee OA with pain in the same knee at both index time point (48-months) and one year prior to that date were included (n=1984). Knee pain was measured using the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) pain sub-scale, by reference to the index knee (the knee with the highest WOMAC pain sub-scale score at baseline). Questionnaire items were selected to assess the 7 available characteristics identified by Akin-Akinoyeoye et al.[1], from which a single CMT factor was calculated by confirmatory factor analysis. Anxiety, fatigue and cognitive difficulties were assessed by single items, depression and sleep disturbance represented by multiple items, and catastrophising by using the Coping Strategies Questionnaire – Catastrophising sub-scale. Pain distribution was defined as a sum of other painful joints at or below the hip. A CMT factor was derived from the 7 characteristics using confirmatory factor analysis. The association between the CMT factor score and 24-month pain (adjusted for baseline pain, radiographic OA (Kellgren-Lawrence (KL) scale) and demographic confounders) was investigated using generalised linear regression with a negative binomial link function.

**Results:** At baseline, participants had a mean (SD) age 65(9) years, a BMI 26.6 (5.6) kg/m², 60% were female, 19.8% were African American, KL score was 1.92(1.35) indicating that the majority of the cohort had radiographic OA. Model diagnostics informed the CMT model, with the final model having an RMSEA of 0.073 (90%CI 0.070-0.076). Data were consistent with a single factor model for CMT. In the multivariable model, higher baseline CMT scores were significantly associated with 24-month WOMAC pain scores, with or without adjustment for baseline pain and other covariates, including KL score (multivariable model: std beta=0.173 (SE=0.027), p=0.004). Association of baseline CMT was of similar magnitude as a sum of other painful joints at or below the hip. A CMT factor was derived as a single item using the Coping Strategies Questionnaire – Catastrophising sub-scale. A CMT factor was calculated by confirmatory factor analysis. The association between the CMT factor score and 24-month pain (adjusted for baseline pain, radiographic OA (Kellgren-Lawrence (KL) scale) and demographic confounders) was investigated using generalised linear regression with a negative binomial link function.

**Conclusion:** CMT predicts worse pain prognosis with a similar magnitude to radiographic OA even after adjustment for other factors. A self-report tool which included items relevant to the characteristics included in the CMT may help to select people with OA knee pain with unfavourable pain prognosis. Poor outcomes related to central pain mechanisms or to joint structural damage might be amenable to treatments addressing central or peripheral pain mechanisms respectively.

**REFERENCES:**

**Acknowledgements:** This abstract was prepared using an Osteoarthritis Initiative (OAI) public use data set and does not necessarily reflect the opinions of views of the OAI investigators, the NIH, or private funding partners. The authors wish to thank the participants, principal investigators, co-investigators and staff of all the hospitals who have contributed data to the OAI. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the National Institutes of Health.

**Disclosures of Interests:** Samuel Holden: None declared. David McWilliams Grant/research support from: Pfizer and Eli Lilly. Stephanie Smith: None declared. David Walsh Consultant of: Pfizer, Eli Lilly, AbbVie and GlaxoSmithKline, Grant/research support from: Pfizer and Eli Lilly

**DOI:** 10.1136/annrheumdis-2021-eular.1595

### Table 1. Adjusted regression coefficients for analysed variables against WOMAC pain at 24-months

<table>
<thead>
<tr>
<th>Variables</th>
<th>Std beta (SE)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>-0.096 (0.101)</td>
<td>0.344</td>
</tr>
<tr>
<td>Age, y</td>
<td>-0.001 (0.006)</td>
<td>0.881</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>0.017 (0.010)</td>
<td>0.088</td>
</tr>
<tr>
<td>Index Knee Kellgren-Lawrence Score</td>
<td>0.164 (0.038)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CMT Factor Score</td>
<td>0.173 (0.060)</td>
<td>0.004</td>
</tr>
<tr>
<td>Baseline Pain</td>
<td>0.657 (0.035)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

n=1421, rows in bold indicate significant association (p<0.05), associations adjusted for race and ethnicity

### Background:
Complex regional pain syndrome (CRPS) is a rare painful condition that usually appears after trauma or surgery of the extremities. Symptoms include pain, sensory, sudomotor and vasomotor disturbances, trophic changes and impaired motor function. The course varies from mild to chronic disease with a high impact on daily functioning and quality of life. In skin tissue, sustained inflammatory, fibrotic processes together with reduced epidermal nerve fibers are reported. Neurotrophins and their receptors are mediators in cell-to-cell communication and key mediators of pain signaling.

**Objectives:** The aim of this study was to identify differential expression of neurotrophins and their receptors in the skin and skin fibroblasts of patients with CRPS.

**Methods:** Healthy controls (HC) and patients with acute CRPS with symptoms for less than 6 months fulfilling the Budapest criteria were recruited. Pain scores were evaluated by numeric rating scale (0=no pain, 100=maximal) and body perception was assessed using the Bath Body Perception Disturbance Scale (BBPDS) (0=no perception disturbance, 57=maximal perception disturbance).

Skin biopsies of the affected and/or non-affected side were taken. Immunohistochemistry on formalin-fixed, paraffin-embedded skin tissue slides was used to show NT3 expression in skin tissues. Blinded analysis was done by an experienced dermato-pathologist determined staining graded by 0= none, 1= sparse, 2=moderate, 3= dense. Skin fibroblasts were isolated from skin biopsies by outgrowth cultures (CRPS, affected side, n=6 and HC, n=5). Cells (passage 3-6) were starved and subsequently stimulated with TNFα (10 ng/ml) or TGFβ (10 ng/ml) for 24 h. NT3 protein expression in cell culture supernatants was measured by quantitative real time PCR and quantified using the ΔΔCq method with GAPDH as a reference gene. ELISA was used to analyze NT3 protein expression in cell culture supernatants.

**Results:** In 5 of 9 patients with CRPS immunohistological staining of NT3 showed an higher expression (from low to moderate) in the affected side versus the non-affected side. In 4 of 9 patients the expression of NT3 was high in the non-affected side (moderate/dense) and stayed high in the affected side. Of interest, the patients with increasing expression of NT3 in the affected side showed increased pain scores (max pain 80 +/- 10.95, n=5 versus 48.16 +/- 18.16, n=4, p=0.059 and changed body perception 26.8 +/- 8.68 n=5 versus 6.5 +/- 3.91, n=4, p=0.016).

Isolated skin fibroblasts from the affected side of patients with CRPS compared to healthy skin fibroblasts showed higher basal gene expression of NT3 (log fold-change= 1.9 +/- 0.4, p=0.005) and NGFR (log fold-change= 3.6 +/- 2.1, p=0.014). TNFα stimulated CRPS skin fibroblasts showed higher expression for NT3 (log fold-change= 2.1 +/- 1.2, p=0.002) compared to HC. TGFβ stimulated skin fibroblasts of patients with CRPS showed higher expression of NT3 (log fold-change= 1.4 +/- 0.8, p=0.019), NGFR (log fold-change= 2.6 +/- 1.8, p=0.036) and TrkB and TrkC) was measured by quantitative real time PCR and quantified using the ΔΔCq method with GAPDH as a reference gene. ELISA was used to analyze NT3 protein expression in cell culture supernatants.
mean= 6.3 +/- 1.8 pg/ml, p=0.25). After TNFα stimulation, protein level of NT3 was significantly higher in CRPS skin fibroblasts (CRPS mean= 10.6 +/- 2.4 pg/ml, HC mean= 4.8 +/- 1.3 pg/ml, p=0.004).

Conclusion: These data indicate a new role of skin fibroblasts in CRPS. Differential basal and stimulated expression of NT3, the receptor for NT3 (TrkC) and NGFR, the common receptor for all neurotrophins, indicates deregulated communication of fibroblasts with the sensory nerve fibers in CRPS. This might contribute to the dysregulated healing processes and sustained pain.

Disclosure of Interests: Sanne Stroeve: None declared, Stefani Dudić: None declared, Isabel Kolm: None declared, Irina Heggl: None declared, Nick Herger: None declared, Sabrina Catanzaro: None declared, Andreas Schweizer: None declared, Maurizio Calcagni: Speakers bureau: Arthrex, Consultant of: Medartis, None declared, Sabrina Catanzaro: None declared, Andreas Schweizer: None declared, Isabel Kolm: None declared, Irina Heggli: None declared, Nick Herger: Disclosure of Interests: Sanne Stroeve: None declared, Stefan Dudli: None declared.

References:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.830

CP0086
GENDER-DERIVED INFLUENCE ON CLINICAL MANIFESTATIONS, DEPRESSIVE SYMPTOMS AND BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) SERUM LEVELS IN PATIENTS AFFECTED BY FIBROMYALGIA

C. Gioia1, B. Lucchino1, C. Iannuccelli1, G. Dolcini1, M. Di Franco1. 1Sapienza Università di Roma, Reumatologia, Dipartimento di Scienze Cliniche, Internistiche, Anestesioligiche e Cardiovascolari, Sapienza Università di Roma, Roma, Italy

Background: Fibromyalgia (FM) is a common rheumatic disease characterized by chronic widespread pain, sleep and mood disorders. A higher prevalence of FM in women compared with men is well known, although the specific differences in clinical manifestations related to gender are still poorly defined. Brain-Derived Neurotrophic Factor (BDNF) is an endogenous growth factor that gained attention for its potential as biomarker of several diseases, including FM and depression.

Objectives: The aims of this study were to investigate gender-related difference among males and females affected by FM in clinical manifestations, depressive features and BDNF serum level, evaluating also the diagnostic potential of the latter.

Methods: We consecutively enrolled adult patients affected by FM (ACR 2016) referring to our out-patient clinic. Each subject underwent clinical and answered to questionnaires for the severity of FM symptoms (Revised Fibromyalgia Impact Questionnaire, R-FIQ) and depressive symptoms (Beck Depression Inventory-II, BDI-II). We collected blood samples from a subgroup of patients of both sexes, matched for age, for BDNF serum level dosage through ELISA. BDNF levels were assessed also in a control group, matched for sex and age.

Results: The cohort was composed by 201 FM patients (172 F, 29 M), mean age 49.13. Females showed higher values of R-FIQ total score (p=0.0005) as well the specific items of the R-FIQ for pain (p=0.013), fatigue (p=0.014), memory problems (p=0.007), tenderness to touch (p=0.0001), balance problems (p=0.001) and sensitivity to environmental stimuli (p=0.012) when compared with males (fig. 1). There was no difference in BDI-II between males and females, but notably male patients reported a significantly higher frequency of coexisting depressive disorder (p=0.038) (fig. 2). Serum BDNF levels were evaluated in 40 FM patients and 40 healthy controls (HC) (F:M 1:1). BDNF levels were significantly lower in FM patients compared with HC (p<0.0001). Among FM patients, BDNF levels were lower in males compared with females (p<0.0001) (fig.3). BDNF did not correlate with any clinical and clinimetric parameter. BDNF showed a good diagnostic performance (AUC=0.89, CI95%=0.82-0.9630, p<0.0001) (fig. 4). At a cut-off value <6.47 ng/dl, BDNF showed a specificity of 75% and a sensibility of 92.51%, (CI 95%=79,68-97.35) for FM identification (LR=3.692).

Conclusion: FM clinical manifestations are strongly dependent on gender. While females present a more severe disease and a higher burden of symptoms, mood disorders tend to be a major characteristic of males with FM. Reduced BDNF serum levels have been reported as typical of depressive disorders. Our findings of lower BDNF levels in male FM patients compared with females support this hypothesis. BDNF have potential as biomarker of the disease and should be validated in larger cohorts.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2021-eular.3326

CP0087
COMORBIDITIES IN HAND OSTEOARTHRITIS PATIENTS: PREVALENCE AND IMPACT ON PAIN AND PAIN SENSITIZATION

E. Muiroonry1, T. Nego2, H. Solveig Dagfinrud1,2, H. Berner Hammer1,2, P. Sten Pettersen1, T. L. Gaarden5,6, K. Engedal1,2, T. K. Kvi1,2, K. Magnusson5, I. K. Haugen2, Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway; 2Boston University School of Medicine, Section of Rheumatology, Boston, United States of America; 3University of Oslo, Department for Interdisciplinary Health Sciences, Oslo, Norway; 4University of Oslo, Department of Orthopaedics, Oslo, Norway; 5Diakonhjemmet sykehus, Alderspsykiatrisk Avdeling, Oslo, Norway; 6University of Oslo, Faculty of Medicine, Oslo, Norway; 7Norwegian Centre of Ageing and Health, Norwegian Centre of Ageing and Health, Oslo, Norway; 8University of Oslo, Department of Geriatric Medicine, Oslo, Norway; 9University of Oslo, Division of Orthopaedic Surgery, Oslo, Norway; 10 Lund University, Department of Clinical Sciences, Lund, Sweden

Background: Pain is a hallmark symptom of hand osteoarthritis (OA). A subset of people with hand OA display centrally driven pain characteristics. Pain is driven by person-related factors, but how comorbidities are related to the hand OA pain experience is undetermined. Changes in pain pathophysiology and pain levels by for instants low-grade inflammation, might explain the link.

Objectives: The purpose of this study was to determine whether the burden of comorbidities or the individual comorbidities were associated with pain and pain sensitization in persons with hand OA.

Methods: These cross-sectional analyses included 282 participants with hand OA from the Nor-Hand study. Comorbidities were assessed by an index (subcales: Disease, Limitation and Treatment, (0-45 scale)) by Sangha et al. The participants completed pain questionnaires; Numeric Rating Scale (NRS) hand pain (0-10) and all joints (0-10), Australian/Canadian (AUSCAN) hand pain subscale (0-20 scale), Western Ontario & McMaster Universities Arthritis Index (WOMAC) pain subscale (0-20) and homunculus (painful joint sites last six weeks, (0-18)). Pressure pain threshold (PPT, handheld algometer, kg/cm²) at tibialis anterior and trapezius and Temporal summation (TS) at the distal radialar joint targeted with weighted probe (x10), assessed central pain sensitization. TS-delta was calculated of the first and peak measure of the fifth or tenth tap. Linear regression was used to examine all relations, while adjusted for age, sex, body mass index and education.

Results: The participants (89% women, median (IQR) age: 61 (57-66)) showed broad range in pain severity. Most frequent comorbidities were back pain (n=170, 60%), hypertension (n= 85, 30%), stomach ulcer/abdominal disease (n=62, 22%) and depression (n=46, 16%). 281 (99.3%) participants reported >1

REFERENCES: